A Study Of Experimental PF-06647020 For Adult Patients With Advanced Solid Tumors
This study will try to find the optimal dose of PF-06647020 in patients with ovarian cancer (OVCA) or non-small cell lung cancer (NSCLC).
- for people ages 18 years and up (full criteria)
- at UC Davis
- study startedestimated completion
Neoplasms ADC PF-06647020 solid tumors tumors neoplasm metastasis TNBC triple negative breast cancer NSCLC non small cell lung cancer advanced metastatic breast cancer ovarian cancer OVCA Fluconazole PF-06647020 combined with Avelumab
- in progress, not accepting new patients
- Start Date
- Completion Date
- To obtain contact information for a study center near you, click here.
- Phase 1
- Study Type
- Last Updated